



THE WHITE HOUSE  
WASHINGTON

# COVID-19 Press Briefing

February 16, 2022



# Daily Change in COVID-19 Cases, US

January 22, 2020 – February 14, 2022

TOTAL Cases Reported Since 1/22/20

**77,837,693**

NEW Cases Reported to CDC on 2/14/22

**203,533**

Change in 7-Day Case Average


**-39.9%**

Current 7-Day Case Average (2/8/22 - 2/14/22)

**146,922**

Prior 7-Day Case Average (2/1/22 - 2/7/22)

**244,559**



# New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – February 13, 2022

Patients Currently Hospitalized with COVID on 2/13/22

**68,505**

New Admissions on 2/13/22

**6,866**

Peak in New Admissions (1/12/22)

**23,061**

Change in 7-Day Average of New Admissions


**-28.1%**

Current 7-Day Average of New Admissions (2/7/22 - 2/13/22)

**9,523**

Prior 7-Day Average of New Admissions (1/31/22 - 2/6/22)

**13,236**



# Daily Change in COVID-19 Deaths, US

January 22, 2020 – February 14, 2022

TOTAL Deaths Reported Since 1/22/2020

**920,097**

NEW Deaths Reported to CDC on 2/14/22

**2,938**

Change in 7-Day Death Average

**-8.8%**

Current 7-Day Death Average (2/8/22 - 2/14/22)


**2,208**

Prior 7-Day Death Average (2/1/22 - 2/7/22)

**2,422**

Forecasted Total Deaths by week ending (03/05/22)

**942,000 to 978,000**



# **Will I Need a 4<sup>th</sup> COVID-19 Shot?**



# What We Know So Far


---

- **Data from multiple studies of vaccine effectiveness show that for immunocompetent people, a single booster shot provides high levels of protection over time against severe disease caused by Omicron**
- **For many immunocompromised people, a 2nd booster shot (4th dose) is recommended**
- **New CDC data indicate that booster shots are safe and well-tolerated**




# United Kingdom: Vaccine Effectiveness Against Hospitalization with Omicron

Two doses of Pfizer/BioNTech vaccine with a Pfizer/BioNTech or Moderna vaccine booster dose



Source: UK Health Security Agency, February 10, 2022

# COVID-19 Vaccine Effectiveness Against COVID-19-Associated Hospitalization During Omicron Period, VISION Network, 10 U.S. States



Source: JM Ferdinands et al. *MMWR*, 2/11/2022.





## Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults – United States, September 22, 2021 - February 6, 2022

- Data reviewed data from two vaccine safety monitoring systems, **v-safe** and the **Vaccine Adverse Event Reporting System (VAERS)**
- People 18+ years who received the same mRNA vaccine brand for all their vaccinations experienced fewer adverse reactions following the booster dose, than they did after their second dose.
- 92% of reports to VAERS were not considered serious, and headache, fever, and muscle pain were the most reported reactions. V-safe data found medical care was rarely received after a booster dose


**The dynamics of the COVID-19 outbreak continue to point in a sharp downward direction**



**Vaccination and boosting will be critical in maintaining that downward trajectory, particularly for severe disease leading to hospitalization**



**The potential future requirement for an additional boost (4th) shot for mRNA and 3rd shot for J&J is being carefully evaluated**





THE WHITE HOUSE  
WASHINGTON

WH.GOV